NEW YORK (GenomeWeb News) – CombiMatrix today said that it has received notice from Nasdaq that it has regained full compliance with the exchange's minimum bid continued listing requirement.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.
The new Riken president outlines some of his plans for the institute.
The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.
An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.